Core Viewpoint - The announcement highlights a collaboration between HBM Alpha Therapeutics and Spruce Biosciences to develop novel CRH-targeted therapies for various diseases, indicating a strategic move in the biopharmaceutical sector [1] Group 1: Partnership Details - HBM Alpha Therapeutics has entered into a licensing and collaboration agreement with Spruce Biosciences Inc. to advance new CRH-targeted therapies [1] - Under the agreement, HBMAT and its affiliates will receive warrants related to minority equity to purchase common stock of Spruce [1] Group 2: Equity Stake - As of January 19, 2026, the company and HBMAT will exercise the warrants, resulting in the company holding approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]
和铂医药-B：根据与Spruce订立的授权及合作协议行使认股权证